For most of the past decade, the story of 3D printing in medicine was a story about shape. Patient-specific anatomy, impossible geometries, surgical guides tailored to a single body, frequently touted as “complexity for free”. The printer’s magic was that it could make forms that would be impossible or very expensive to make by mold injection. In 2026, the center of gravity has moved. The defining question is no longer “What shape can we print?” but rather “What material can we print, and will a regulator ever accept it?” That shift has a name worth adopting: the move toward regulator-legible material systems.

What “legible” actually means

A regulator does not approve a material just because it is “cool”. A regulator approves evidence, or documentation, that a material behaves the same way every time, degrades on a predictable timeline, releases nothing harmful, and can be manufactured to a specification you can point to. If a material cannot be described in those terms, it is effectively illegible to an agency like the FDA or a European notified body operating under the EU MDR. They have no framework within which to say yes. “Legibility,” then, is the property of being readable by the people who decide whether something can be used in a human body.

For years, printed biomaterials sat squarely in the illegible zone. A laboratory could print a stunning scaffold, but the material was a one-off: no agreed test methods, batch-to-batch variability, a degradation profile no one had fully characterized, and mechanical properties that shifted with every change of machine or setting. It was brilliant science that a reviewer had no way to sign off on, and just as importantly, no way for a company to build a product or an investor to underwrite a business around.

Why 3D printable biomaterials are uniquely hard to read

The core difficulty is that in additive manufacturing, the material and the process are inseparable. A conventional implant polymer arrives with a datasheet; you can reason about it in isolation. A photopolymer resin cured layer-by-layer on a specific printer, at a specific wavelength, with a specific post-cure and wash step, is a different material depending on how it was made. Residual monomer, degree of cure, layer adhesion, porosity, and even sterilization can each move the biological and mechanical outcome. The FDA’s 2017 guidance, Technical Considerations for Additive Manufactured Medical Devices, makes exactly this point: it asks manufacturers to control and document the entire workflow — design, build parameters, post-processing, cleaning, and testing, because the finished device’s safety is a function of the whole chain, not the starting resin alone.

This is why the field has begun talking about material systems rather than just materials. A material system is the full package that makes a printed biomaterial usable and clearable: the feedstock chemistry plus the validated print parameters, the post-processing and sterilization steps, and the standardized test methods that prove the finished part performs. Change one link, and you may have changed the material; the system is the unit that must be defined, controlled, and, importantly, reproduced.

The machinery of legibility: standards

Legibility is manufactured by standards. They are the shared language that turns a private lab result into something an outside reviewer can trust. Several bodies of work matter here. ISO/ASTM 52900 and the broader 52900 series provide additive manufacturing with common terminology and process definitions. ASTM Committee F42 develops additive manufacturing standards, while ASTM Committee F04 governs medical and surgical materials and devices, including the absorbable polymers at the heart of many printed scaffolds. ISO 10993 defines how the biological safety of a material is evaluated (cytotoxicity, sensitization, and the rest), and quality-system standards such as ISO 13485 wrap the whole operation in documented process control. When a new absorbable polymer gains an agreed test method through F04/F42, it crosses a threshold: it stops being “interesting research” and becomes something a regulator can read.

Legibility across the three material tracks

The push toward legibility is playing out simultaneously across the field’s three frontiers. In the soft track, function-first bioresins and degradable photopolymers, the challenge is characterizing the degradation and drug-release behavior of materials that are, by design, changing over time. In hard-track ion-releasing ceramics and bioactive glass, legibility means controlling surface chemistry and post-processing to ensure that a printed or coated implant integrates with bone predictably. In the structural track, titanium and architected lattices mean proving that a geometry-defined, load-bearing material fatigues and performs as its design promises. Each track has the same underlying task: converting a novel material into a documented, reproducible, testable system.

Why this is an investment thesis, not just a regulatory chore

The commercial consequence is the part founders and investors should internalize. The moment a class of printed biomaterial becomes regulator-legible, it crosses from research risk into a fundable, buildable product. Legibility is what lets a material become the “investment-grade core” of a device rather than a promising figure in a paper. As the healthcare 3D-printing market races toward roughly $33 billion by 2031, the binding constraint is shifting from the printer to the material and the surrounding system. The companies that win will be the ones that make their materials legible fastest.

Where this conversation is happening

These are exactly the questions on the table at 3DHEALS’ “Biomaterials Frontier for 3D Printing” virtual event (September 10, 2026), which convenes the researchers, founders, and industry leaders defining the shift — including a bioresorbable-polymer and ASTM standards leader from Poly-Med, a biofabrication founder scaling human collagen (Arrakis Bio), an AI-driven materials-discovery pioneer from Johns Hopkins, a 4D-materials founder, an architected-meta-biomaterials researcher, and a calcium-phosphate bioceramics veteran in the moderator’s chair. If the frontier of 3D-printed medicine is the move from printing structure to printing function, and from lab novelty to regulator-legible systems, then this is a session built around the people making that move real. Details and free registration: https://3dheals.com/biomaterials-frontier/.

References

1.  U.S. Food & Drug Administration. Technical Considerations for Additive Manufactured Medical Devices — Guidance for Industry and FDA Staff. December 2017. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-additive-manufactured-medical-devices

2.  ISO/ASTM 52900:2021. Additive manufacturing — General principles — Fundamentals and vocabulary. https://www.iso.org/standard/74514.html

3.  ASTM International, Committee F42 on Additive Manufacturing Technologies. https://www.astm.org/committee-f42

4.  ASTM International, Committee F04 on Medical and Surgical Materials and Devices. https://www.astm.org/committee-f04

5.  ISO 10993-1:2018. Biological evaluation of medical devices — Part 1. https://www.iso.org/standard/68936.html

6.  ISO 13485:2016. Medical devices — Quality management systems — Requirements for regulatory purposes. https://www.iso.org/standard/59752.html

7.  European Union. Regulation (EU) 2017/745 on medical devices (MDR). https://eur-lex.europa.eu/eli/reg/2017/745/oj

8.  Mordor Intelligence. Healthcare 3D Printing Market — Size, Share & Forecast (2026–2031). https://www.mordorintelligence.com/industry-reports/global-3d-printing-market-in-healthcare-industry-industry

9.  3DHEALS. Biomaterials Frontier for 3D Printing (virtual event, Sept 10, 2026). https://3dheals.com/biomaterials-frontier/